New drug candidate BL-M02D1 enters human trials for Hard-to-Treat cancers

NCT ID NCT05339685

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 21 times

Summary

This early-phase study tests a new drug called BL-M02D1 in people with advanced triple negative breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 82 participants will take part in two stages to determine the right dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Yueyang People's Hospital

    Yueyang, Hunan, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

Conditions

Explore the condition pages connected to this study.